ClinicalTrials.Veeva

Menu

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

N

Nile Therapeutics

Status and phase

Completed
Phase 2

Conditions

Acute Decompensated Heart Failure

Treatments

Drug: CD-NP

Study type

Interventional

Funder types

Industry

Identifiers

NCT00839007
NIL-CDNP-CT005

Details and patient eligibility

About

The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.

Enrollment

77 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  1. Hospitalized for acute decompensated heart failure.
  2. Systolic blood pressure ≥ 115 mmHg and ≤ 200 mmHg, and diastolic blood pressure ≥ 60 mmHg and ≤ 110 mmHg at screening
  3. Renally compromised.
  4. Female patients must be post-menopausal or surgically sterile.

Key Exclusion Criteria:

  1. Acute or suspected acute myocardial infarction (AMI) or troponin levels > 3X the upper limit of normal at the institution's local laboratory
  2. Cardiogenic shock
  3. Evidence of uncorrected volume or sodium depletion other clinical condition that would predispose the patient to adverse events
  4. Clinically significant aortic or mitral valve stenosis
  5. Temperature >38°C (oral or equivalent), sepsis or active infection requiring IV anti-microbial treatment
  6. ADHF due to significant arrhythmias
  7. Severe renal failure defined as creatinine clearance < 30 mL/min
  8. Current or planned ultrafiltration, hemofiltration, or dialysis
  9. Significant pulmonary disease
  10. Major neurologic event, including cerebrovascular events in the prior 60 days.
  11. Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy (not including restrictive mitral filling patterns)
  12. Known hypersensitivity or allergy to natriuretic peptide or its components, nesiritide, other natriuretic peptides or related compounds

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

77 participants in 7 patient groups, including a placebo group

A
Experimental group
Description:
Dose 1 of CD-NP
Treatment:
Drug: CD-NP
B
Experimental group
Description:
Dose 2 of CD-NP
Treatment:
Drug: CD-NP
C
Experimental group
Description:
Dose 3 of CD-NP
Treatment:
Drug: CD-NP
D
Experimental group
Description:
Dose 4 of CD-NP
Treatment:
Drug: CD-NP
E
Experimental group
Description:
Dose 5 of CD-NP
Treatment:
Drug: CD-NP
F
Experimental group
Description:
Dose 6 of CD-NP
Treatment:
Drug: CD-NP
G
Placebo Comparator group
Description:
Placebo
Treatment:
Drug: CD-NP

Trial contacts and locations

21

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems